#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Early diagnosis and treatment of human malaria reduces disease , prevents deaths , and contributes to reduced transmission .
2-1	16-21	Early	event[2]|event[3]	new[2]|new[3]	coref|coref	5-13[40_2]|13-15[150_3]
2-2	22-31	diagnosis	event[2]|event[3]	new[2]|new[3]	_	_
2-3	32-35	and	event[3]	new[3]	_	_
2-4	36-45	treatment	event[3]|event[4]	new[3]|new[4]	_	_
2-5	46-48	of	event[3]|event[4]	new[3]|new[4]	_	_
2-6	49-54	human	event[3]|event[4]|abstract[5]	new[3]|new[4]|new[5]	coref	3-6[0_5]
2-7	55-62	malaria	event[3]|event[4]|abstract[5]	new[3]|new[4]|new[5]	_	_
2-8	63-70	reduces	_	_	_	_
2-9	71-78	disease	event	new	coref	10-5
2-10	79-80	,	_	_	_	_
2-11	81-89	prevents	_	_	_	_
2-12	90-96	deaths	event	new	_	_
2-13	97-98	,	_	_	_	_
2-14	99-102	and	_	_	_	_
2-15	103-114	contributes	_	_	_	_
2-16	115-117	to	_	_	_	_
2-17	118-125	reduced	abstract[8]	new[8]	coref	7-24[0_8]
2-18	126-138	transmission	abstract[8]	new[8]	_	_
2-19	139-140	.	_	_	_	_

#Text=Detection of antibody response against malaria antigens is often done through Enzyme-Linked Immunosorbent Assay ( ELISA ) ; many of these diagnostic assays are designed with a single antigen or with recombinant antigens of different stages of the parasites ( tissue infection or blood ) , where merozoite surface proteins can be detected , and have demonstrated good sensitivity and specificity .
3-1	141-150	Detection	abstract[9]	new[9]	_	_
3-2	151-153	of	abstract[9]	new[9]	_	_
3-3	154-162	antibody	abstract[9]|substance|abstract[11]	new[9]|new|new[11]	coref	5-27
3-4	163-171	response	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-5	172-179	against	abstract[9]|abstract[11]	new[9]|new[11]	_	_
3-6	180-187	malaria	abstract[9]|abstract[11]|abstract|substance[13]	new[9]|new[11]|giv|new[13]	coref|coref	3-32[20_13]|5-16
3-7	188-196	antigens	abstract[9]|abstract[11]|substance[13]	new[9]|new[11]|new[13]	_	_
3-8	197-199	is	_	_	_	_
3-9	200-205	often	_	_	_	_
3-10	206-210	done	_	_	_	_
3-11	211-218	through	_	_	_	_
3-12	219-232	Enzyme-Linked	event|abstract[16]	new|new[16]	appos	3-16[0_16]
3-13	233-246	Immunosorbent	abstract|abstract[16]	new|new[16]	_	_
3-14	247-252	Assay	abstract[16]	new[16]	_	_
3-15	253-254	(	_	_	_	_
3-16	255-260	ELISA	abstract	giv	coref	5-8
3-17	261-262	)	_	_	_	_
3-18	263-264	;	_	_	_	_
3-19	265-269	many	_	_	_	_
3-20	270-272	of	_	_	_	_
3-21	273-278	these	abstract[18]	new[18]	_	_
3-22	279-289	diagnostic	abstract[18]	new[18]	_	_
3-23	290-296	assays	abstract[18]	new[18]	_	_
3-24	297-300	are	_	_	_	_
3-25	301-309	designed	_	_	_	_
3-26	310-314	with	_	_	_	_
3-27	315-316	a	object[19]	new[19]	_	_
3-28	317-323	single	object[19]	new[19]	_	_
3-29	324-331	antigen	object[19]	new[19]	_	_
3-30	332-334	or	_	_	_	_
3-31	335-339	with	_	_	_	_
3-32	340-351	recombinant	substance[20]	giv[20]	coref	6-5[71_20]
3-33	352-360	antigens	substance[20]	giv[20]	_	_
3-34	361-363	of	substance[20]	giv[20]	_	_
3-35	364-373	different	substance[20]|abstract[21]	giv[20]|new[21]	_	_
3-36	374-380	stages	substance[20]|abstract[21]	giv[20]|new[21]	_	_
3-37	381-383	of	substance[20]|abstract[21]	giv[20]|new[21]	_	_
3-38	384-387	the	substance[20]|abstract[21]|animal[22]	giv[20]|new[21]|new[22]	appos	3-41[25_22]
3-39	388-397	parasites	substance[20]|abstract[21]|animal[22]	giv[20]|new[21]|new[22]	_	_
3-40	398-399	(	_	_	_	_
3-41	400-406	tissue	object|abstract[24]|animal[25]	new|new[24]|giv[25]	coref|coref	5-37[48_24]|5-62[56_25]
3-42	407-416	infection	abstract[24]|animal[25]	new[24]|giv[25]	_	_
3-43	417-419	or	animal[25]	giv[25]	_	_
3-44	420-425	blood	animal[25]|substance	giv[25]|new	coref	4-18[36_0]
3-45	426-427	)	_	_	_	_
3-46	428-429	,	_	_	_	_
3-47	430-435	where	_	_	_	_
3-48	436-445	merozoite	abstract|object[29]	new|new[29]	_	_
3-49	446-453	surface	place|object[29]	new|new[29]	_	_
3-50	454-462	proteins	object[29]	new[29]	_	_
3-51	463-466	can	_	_	_	_
3-52	467-469	be	_	_	_	_
3-53	470-478	detected	_	_	_	_
3-54	479-480	,	_	_	_	_
3-55	481-484	and	_	_	_	_
3-56	485-489	have	_	_	_	_
3-57	490-502	demonstrated	_	_	_	_
3-58	503-507	good	abstract[30]	new[30]	_	_
3-59	508-519	sensitivity	abstract[30]	new[30]	_	_
3-60	520-523	and	_	_	_	_
3-61	524-535	specificity	abstract	new	_	_
3-62	536-537	.	_	_	_	_

#Text=However , many individuals cannot be easily diagnosed due to the low levels of antibodies present in their blood .
4-1	538-545	However	_	_	_	_
4-2	546-547	,	_	_	_	_
4-3	548-552	many	person[32]	new[32]	ana	4-18[0_32]
4-4	553-564	individuals	person[32]	new[32]	_	_
4-5	565-571	cannot	_	_	_	_
4-6	572-574	be	_	_	_	_
4-7	575-581	easily	_	_	_	_
4-8	582-591	diagnosed	_	_	_	_
4-9	592-595	due	_	_	_	_
4-10	596-598	to	_	_	_	_
4-11	599-602	the	abstract[33]	new[33]	_	_
4-12	603-606	low	abstract[33]	new[33]	_	_
4-13	607-613	levels	abstract[33]	new[33]	_	_
4-14	614-616	of	abstract[33]	new[33]	_	_
4-15	617-627	antibodies	abstract[33]|substance	new[33]|new	coref	6-3[69_0]
4-16	628-635	present	_	_	_	_
4-17	636-638	in	_	_	_	_
4-18	639-644	their	person|substance[36]	giv|giv[36]	coref	5-31[46_0]
4-19	645-650	blood	substance[36]	giv[36]	_	_
4-20	651-652	.	_	_	_	_

#Text=In this context , the use of ELISA as a tool for laboratory diagnosis of malaria has some limitations , namely : ( i ) low antibody titres presented by individuals in the acute phase of infection ; ( ii ) many Plasmodium sp . are involved in human malaria ; ( iii ) different evolutionary forms of Plasmodium spp. during infection and life cycle ; and ( iv ) different resistance and susceptibility profiles during infection , and consequently in the immunity profile against malaria parasites .
5-1	653-655	In	_	_	_	_
5-2	656-660	this	abstract[37]	new[37]	_	_
5-3	661-668	context	abstract[37]	new[37]	_	_
5-4	669-670	,	_	_	_	_
5-5	671-674	the	abstract[38]	new[38]	coref	7-17[85_38]
5-6	675-678	use	abstract[38]	new[38]	_	_
5-7	679-681	of	abstract[38]	new[38]	_	_
5-8	682-687	ELISA	abstract[38]|abstract	new[38]|giv	coref	12-20[137_0]
5-9	688-690	as	abstract[38]	new[38]	_	_
5-10	691-692	a	abstract[38]	new[38]	_	_
5-11	693-697	tool	abstract[38]	new[38]	_	_
5-12	698-701	for	abstract[38]	new[38]	_	_
5-13	702-712	laboratory	abstract[38]|event[40]	new[38]|giv[40]	_	_
5-14	713-722	diagnosis	abstract[38]|event[40]	new[38]|giv[40]	_	_
5-15	723-725	of	abstract[38]|event[40]	new[38]|giv[40]	_	_
5-16	726-733	malaria	abstract[38]|event[40]|abstract	new[38]|giv[40]|giv	coref	5-49[52_0]
5-17	734-737	has	_	_	_	_
5-18	738-742	some	abstract[42]	new[42]	_	_
5-19	743-754	limitations	abstract[42]	new[42]	_	_
5-20	755-756	,	_	_	_	_
5-21	757-763	namely	abstract[43]	new[43]	_	_
5-22	764-765	:	abstract[43]	new[43]	_	_
5-23	766-767	(	abstract[43]	new[43]	_	_
5-24	768-769	i	abstract[43]	new[43]	_	_
5-25	770-771	)	abstract[43]	new[43]	_	_
5-26	772-775	low	abstract[45]	new[45]	_	_
5-27	776-784	antibody	substance|abstract[45]	giv|new[45]	_	_
5-28	785-791	titres	abstract[45]	new[45]	_	_
5-29	792-801	presented	_	_	_	_
5-30	802-804	by	_	_	_	_
5-31	805-816	individuals	person[46]	giv[46]	ana	6-16[0_46]
5-32	817-819	in	person[46]	giv[46]	_	_
5-33	820-823	the	person[46]|abstract[47]	giv[46]|new[47]	_	_
5-34	824-829	acute	person[46]|abstract[47]	giv[46]|new[47]	_	_
5-35	830-835	phase	person[46]|abstract[47]	giv[46]|new[47]	_	_
5-36	836-838	of	person[46]|abstract[47]	giv[46]|new[47]	_	_
5-37	839-848	infection	person[46]|abstract[47]|abstract[48]	giv[46]|new[47]|giv[48]	coref	5-62[0_48]
5-38	849-850	;	person[46]|abstract[47]|abstract[48]	giv[46]|new[47]|giv[48]	_	_
5-39	851-852	(	person[46]|abstract[47]|abstract[48]|abstract[51]	giv[46]|new[47]|giv[48]|new[51]	coref	12-27[140_51]
5-40	853-855	ii	person[46]|abstract[47]|abstract[48]|abstract|abstract[51]	giv[46]|new[47]|giv[48]|new|new[51]	_	_
5-41	856-857	)	person[46]|abstract[47]|abstract[48]|abstract[51]	giv[46]|new[47]|giv[48]|new[51]	_	_
5-42	858-862	many	person[46]|abstract[47]|abstract[48]|abstract[51]	giv[46]|new[47]|giv[48]|new[51]	_	_
5-43	863-873	Plasmodium	person[46]|abstract[47]|abstract[48]|substance|abstract[51]	giv[46]|new[47]|giv[48]|new|new[51]	coref	5-59
5-44	874-876	sp	person[46]|abstract[47]|abstract[48]|abstract[51]	giv[46]|new[47]|giv[48]|new[51]	_	_
5-45	877-878	.	_	_	_	_
5-46	879-882	are	_	_	_	_
5-47	883-891	involved	_	_	_	_
5-48	892-894	in	_	_	_	_
5-49	895-900	human	abstract[52]	giv[52]	coref	5-86[0_52]
5-50	901-908	malaria	abstract[52]	giv[52]	_	_
5-51	909-910	;	_	_	_	_
5-52	911-912	(	_	_	_	_
5-53	913-916	iii	_	_	_	_
5-54	917-918	)	_	_	_	_
5-55	919-928	different	abstract[53]	new[53]	_	_
5-56	929-941	evolutionary	abstract[53]	new[53]	_	_
5-57	942-947	forms	abstract[53]	new[53]	_	_
5-58	948-950	of	abstract[53]	new[53]	_	_
5-59	951-961	Plasmodium	abstract[53]|substance	new[53]|giv	coref	12-27
5-60	962-966	spp.	abstract[53]	new[53]	_	_
5-61	967-973	during	abstract[53]	new[53]	_	_
5-62	974-983	infection	abstract[53]|abstract|animal[56]	new[53]|giv|giv[56]	coref|coref	5-77|5-86[67_56]
5-63	984-987	and	abstract[53]|animal[56]	new[53]|giv[56]	_	_
5-64	988-992	life	abstract[53]|animal[56]|abstract|time[58]	new[53]|giv[56]|new|new[58]	_	_
5-65	993-998	cycle	abstract[53]|animal[56]|time[58]	new[53]|giv[56]|new[58]	_	_
5-66	999-1000	;	_	_	_	_
5-67	1001-1004	and	_	_	_	_
5-68	1005-1006	(	_	_	_	_
5-69	1007-1009	iv	person	new	_	_
5-70	1010-1011	)	_	_	_	_
5-71	1012-1021	different	_	_	_	_
5-72	1022-1032	resistance	abstract	new	_	_
5-73	1033-1036	and	_	_	_	_
5-74	1037-1051	susceptibility	abstract|object[62]	new|new[62]	_	_
5-75	1052-1060	profiles	object[62]	new[62]	_	_
5-76	1061-1067	during	object[62]	new[62]	_	_
5-77	1068-1077	infection	object[62]|abstract	new[62]|giv	_	_
5-78	1078-1079	,	_	_	_	_
5-79	1080-1083	and	_	_	_	_
5-80	1084-1096	consequently	object[65]	new[65]	_	_
5-81	1097-1099	in	object[65]	new[65]	_	_
5-82	1100-1103	the	object[65]	new[65]	_	_
5-83	1104-1112	immunity	abstract|object[65]	new|new[65]	_	_
5-84	1113-1120	profile	object[65]	new[65]	_	_
5-85	1121-1128	against	object[65]	new[65]	_	_
5-86	1129-1136	malaria	object[65]|abstract|animal[67]	new[65]|giv|giv[67]	coref|coref	6-8|11-10[127_67]
5-87	1137-1146	parasites	object[65]|animal[67]	new[65]|giv[67]	_	_
5-88	1147-1148	.	_	_	_	_

#Text=Associations among antibodies against parasite antigens and malaria risk areas are not always consistent ; some may depend on parasite antigens and other considerations may be due to the endemic areas of malaria .
6-1	1149-1161	Associations	abstract[68]	new[68]	_	_
6-2	1162-1167	among	abstract[68]	new[68]	_	_
6-3	1168-1178	antibodies	abstract[68]|substance[69]	new[68]|giv[69]	coref	7-9[0_69]
6-4	1179-1186	against	abstract[68]|substance[69]	new[68]|giv[69]	_	_
6-5	1187-1195	parasite	abstract[68]|substance[69]|animal|substance[71]	new[68]|giv[69]|new|giv[71]	coref|coref	6-20|6-20[77_71]
6-6	1196-1204	antigens	abstract[68]|substance[69]|substance[71]	new[68]|giv[69]|giv[71]	_	_
6-7	1205-1208	and	abstract[68]|substance[69]|substance[71]	new[68]|giv[69]|giv[71]	_	_
6-8	1209-1216	malaria	abstract[68]|substance[69]|substance[71]|abstract|place[74]	new[68]|giv[69]|giv[71]|giv|new[74]	coref|coref	6-29[79_74]|6-33
6-9	1217-1221	risk	abstract[68]|substance[69]|substance[71]|abstract|place[74]	new[68]|giv[69]|giv[71]|new|new[74]	coref	9-19[102_0]
6-10	1222-1227	areas	abstract[68]|substance[69]|substance[71]|place[74]	new[68]|giv[69]|giv[71]|new[74]	_	_
6-11	1228-1231	are	_	_	_	_
6-12	1232-1235	not	_	_	_	_
6-13	1236-1242	always	_	_	_	_
6-14	1243-1253	consistent	_	_	_	_
6-15	1254-1255	;	_	_	_	_
6-16	1256-1260	some	person	giv	_	_
6-17	1261-1264	may	_	_	_	_
6-18	1265-1271	depend	_	_	_	_
6-19	1272-1274	on	_	_	_	_
6-20	1275-1283	parasite	person|substance[77]	giv|giv[77]	coref	7-11[0_77]
6-21	1284-1292	antigens	substance[77]	giv[77]	_	_
6-22	1293-1296	and	_	_	_	_
6-23	1297-1302	other	abstract[78]	new[78]	_	_
6-24	1303-1317	considerations	abstract[78]	new[78]	_	_
6-25	1318-1321	may	_	_	_	_
6-26	1322-1324	be	_	_	_	_
6-27	1325-1328	due	_	_	_	_
6-28	1329-1331	to	_	_	_	_
6-29	1332-1335	the	place[79]	giv[79]	_	_
6-30	1336-1343	endemic	place[79]	giv[79]	_	_
6-31	1344-1349	areas	place[79]	giv[79]	_	_
6-32	1350-1352	of	place[79]	giv[79]	_	_
6-33	1353-1360	malaria	place[79]|abstract	giv[79]|giv	ana	7-1
6-34	1361-1362	.	_	_	_	_

#Text=It should be considered that single responses of antibodies against antigens might be inadequate to for use as biomarkers and indicators of malaria transmission intensity .
7-1	1363-1365	It	abstract	giv	coref	7-23
7-2	1366-1372	should	_	_	_	_
7-3	1373-1375	be	_	_	_	_
7-4	1376-1386	considered	_	_	_	_
7-5	1387-1391	that	_	_	_	_
7-6	1392-1398	single	abstract[82]	new[82]	_	_
7-7	1399-1408	responses	abstract[82]	new[82]	_	_
7-8	1409-1411	of	abstract[82]	new[82]	_	_
7-9	1412-1422	antibodies	abstract[82]|substance	new[82]|giv	coref	12-15[136_0]
7-10	1423-1430	against	abstract[82]	new[82]	_	_
7-11	1431-1439	antigens	abstract[82]|substance	new[82]|giv	coref	12-24[138_0]
7-12	1440-1445	might	_	_	_	_
7-13	1446-1448	be	_	_	_	_
7-14	1449-1459	inadequate	_	_	_	_
7-15	1460-1462	to	_	_	_	_
7-16	1463-1466	for	_	_	_	_
7-17	1467-1470	use	abstract[85]	giv[85]	_	_
7-18	1471-1473	as	abstract[85]	giv[85]	_	_
7-19	1474-1484	biomarkers	abstract[85]	giv[85]	_	_
7-20	1485-1488	and	abstract[85]	giv[85]	_	_
7-21	1489-1499	indicators	abstract[85]	giv[85]	_	_
7-22	1500-1502	of	abstract[85]	giv[85]	_	_
7-23	1503-1510	malaria	abstract[85]|abstract|abstract[88]	giv[85]|giv|new[88]	coref	9-21
7-24	1511-1523	transmission	abstract[85]|abstract|abstract[88]	giv[85]|giv|new[88]	_	_
7-25	1524-1533	intensity	abstract[85]|abstract[88]	giv[85]|new[88]	_	_
7-26	1534-1535	.	_	_	_	_

#Text=Other authors have shown that new serological biomarkers can more accurately estimate the recent exposure to P. falciparum not only of a community , but also for several communities .
8-1	1536-1541	Other	person[89]	new[89]	_	_
8-2	1542-1549	authors	person[89]	new[89]	_	_
8-3	1550-1554	have	_	_	_	_
8-4	1555-1560	shown	_	_	_	_
8-5	1561-1565	that	_	_	_	_
8-6	1566-1569	new	abstract[90]	new[90]	_	_
8-7	1570-1581	serological	abstract[90]	new[90]	_	_
8-8	1582-1592	biomarkers	abstract[90]	new[90]	_	_
8-9	1593-1596	can	_	_	_	_
8-10	1597-1601	more	_	_	_	_
8-11	1602-1612	accurately	_	_	_	_
8-12	1613-1621	estimate	_	_	_	_
8-13	1622-1625	the	abstract[91]	new[91]	_	_
8-14	1626-1632	recent	abstract[91]	new[91]	_	_
8-15	1633-1641	exposure	abstract[91]	new[91]	_	_
8-16	1642-1644	to	abstract[91]	new[91]	_	_
8-17	1645-1647	P.	abstract[91]|place|abstract[93]	new[91]|new|new[93]	coref|coref	9-25|9-23[105_93]
8-18	1648-1658	falciparum	abstract[91]|abstract[93]	new[91]|new[93]	_	_
8-19	1659-1662	not	abstract[91]|abstract[93]	new[91]|new[93]	_	_
8-20	1663-1667	only	abstract[91]|abstract[93]|organization[94]	new[91]|new[93]|new[94]	_	_
8-21	1668-1670	of	abstract[91]|abstract[93]|organization[94]	new[91]|new[93]|new[94]	_	_
8-22	1671-1672	a	abstract[91]|abstract[93]|organization[94]	new[91]|new[93]|new[94]	_	_
8-23	1673-1682	community	abstract[91]|abstract[93]|organization[94]	new[91]|new[93]|new[94]	_	_
8-24	1683-1684	,	_	_	_	_
8-25	1685-1688	but	_	_	_	_
8-26	1689-1693	also	_	_	_	_
8-27	1694-1697	for	_	_	_	_
8-28	1698-1705	several	organization[95]	new[95]	_	_
8-29	1706-1717	communities	organization[95]	new[95]	_	_
8-30	1718-1719	.	_	_	_	_

#Text=In 2015 , approximately 3.2 billion people — nearly half of the world ’s population — were at risk of malaria , mainly by P. falciparum .
9-1	1720-1722	In	_	_	_	_
9-2	1723-1727	2015	time	new	_	_
9-3	1728-1729	,	_	_	_	_
9-4	1730-1743	approximately	person[98]	new[98]	appos	9-9[99_98]
9-5	1744-1747	3.2	person[98]	new[98]	_	_
9-6	1748-1755	billion	abstract|person[98]	new|new[98]	_	_
9-7	1756-1762	people	person[98]	new[98]	_	_
9-8	1763-1764	—	_	_	_	_
9-9	1765-1771	nearly	person[99]	giv[99]	_	_
9-10	1772-1776	half	person[99]	giv[99]	_	_
9-11	1777-1779	of	person[99]	giv[99]	_	_
9-12	1780-1783	the	person[99]|person[101]	giv[99]|new[101]	_	_
9-13	1784-1789	world	person[99]|place[100]|person[101]	giv[99]|new[100]|new[101]	_	_
9-14	1790-1792	’s	person[99]|place[100]|person[101]	giv[99]|new[100]|new[101]	_	_
9-15	1793-1803	population	person[99]|person[101]	giv[99]|new[101]	_	_
9-16	1804-1805	—	_	_	_	_
9-17	1806-1810	were	_	_	_	_
9-18	1811-1813	at	_	_	_	_
9-19	1814-1818	risk	abstract[102]	giv[102]	_	_
9-20	1819-1821	of	abstract[102]	giv[102]	_	_
9-21	1822-1829	malaria	abstract[102]|abstract	giv[102]|giv	coref	10-9
9-22	1830-1831	,	abstract[102]	giv[102]	_	_
9-23	1832-1838	mainly	abstract[102]|abstract[105]	giv[102]|giv[105]	coref	11-1[123_105]
9-24	1839-1841	by	abstract[102]|abstract[105]	giv[102]|giv[105]	_	_
9-25	1842-1844	P.	abstract[102]|place|abstract[105]	giv[102]|giv|giv[105]	coref	11-1
9-26	1845-1855	falciparum	abstract[102]|abstract[105]	giv[102]|giv[105]	_	_
9-27	1856-1857	.	_	_	_	_

#Text=After several decades of disease control campaigns , malaria persists as one of the most serious public health problems , not only in endemic countries , but also in non-endemic regions , where the number of cases of imported malaria via tourists and immigrants is on the rise .
10-1	1858-1863	After	_	_	_	_
10-2	1864-1871	several	time[106]	new[106]	_	_
10-3	1872-1879	decades	time[106]	new[106]	_	_
10-4	1880-1882	of	time[106]	new[106]	_	_
10-5	1883-1890	disease	time[106]|abstract|abstract[109]	new[106]|giv|new[109]	coref	11-29[131_0]
10-6	1891-1898	control	time[106]|abstract|abstract[109]	new[106]|new|new[109]	_	_
10-7	1899-1908	campaigns	time[106]|abstract[109]	new[106]|new[109]	_	_
10-8	1909-1910	,	_	_	_	_
10-9	1911-1918	malaria	abstract	giv	coref	10-39[118_0]
10-10	1919-1927	persists	_	_	_	_
10-11	1928-1930	as	_	_	_	_
10-12	1931-1934	one	abstract[111]	new[111]	coref	11-4[124_111]
10-13	1935-1937	of	abstract[111]	new[111]	_	_
10-14	1938-1941	the	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-15	1942-1946	most	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-16	1947-1954	serious	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-17	1955-1961	public	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-18	1962-1968	health	abstract[111]|abstract|abstract[113]	new[111]|new|new[113]	_	_
10-19	1969-1977	problems	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-20	1978-1979	,	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-21	1980-1983	not	abstract[111]|abstract[113]	new[111]|new[113]	_	_
10-22	1984-1988	only	abstract[111]|abstract[113]|place[114]	new[111]|new[113]|new[114]	_	_
10-23	1989-1991	in	abstract[111]|abstract[113]|place[114]	new[111]|new[113]|new[114]	_	_
10-24	1992-1999	endemic	abstract[111]|abstract[113]|place[114]	new[111]|new[113]|new[114]	_	_
10-25	2000-2009	countries	abstract[111]|abstract[113]|place[114]	new[111]|new[113]|new[114]	_	_
10-26	2010-2011	,	_	_	_	_
10-27	2012-2015	but	_	_	_	_
10-28	2016-2020	also	_	_	_	_
10-29	2021-2023	in	_	_	_	_
10-30	2024-2035	non-endemic	place[115]	new[115]	_	_
10-31	2036-2043	regions	place[115]	new[115]	_	_
10-32	2044-2045	,	_	_	_	_
10-33	2046-2051	where	_	_	_	_
10-34	2052-2055	the	abstract[116]	new[116]	_	_
10-35	2056-2062	number	abstract[116]	new[116]	_	_
10-36	2063-2065	of	abstract[116]	new[116]	_	_
10-37	2066-2071	cases	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-38	2072-2074	of	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-39	2075-2083	imported	abstract[116]|abstract[117]|abstract[118]	new[116]|new[117]|giv[118]	coref	11-11[0_118]
10-40	2084-2091	malaria	abstract[116]|abstract[117]|abstract[118]	new[116]|new[117]|giv[118]	_	_
10-41	2092-2095	via	abstract[116]|abstract[117]|abstract[118]	new[116]|new[117]|giv[118]	_	_
10-42	2096-2104	tourists	abstract[116]|abstract[117]|abstract[118]|person	new[116]|new[117]|giv[118]|new	_	_
10-43	2105-2108	and	abstract[116]|abstract[117]|abstract[118]	new[116]|new[117]|giv[118]	_	_
10-44	2109-2119	immigrants	abstract[116]|abstract[117]|abstract[118]|person	new[116]|new[117]|giv[118]|new	_	_
10-45	2120-2122	is	_	_	_	_
10-46	2123-2125	on	_	_	_	_
10-47	2126-2129	the	abstract[121]	new[121]	_	_
10-48	2130-2134	rise	abstract[121]	new[121]	_	_
10-49	2135-2136	.	_	_	_	_

#Text=P. falciparum is one the most lethal species of the malaria parasites that infect humans , and is responsible for the highest number of serious pathologies associated with the disease .
11-1	2137-2139	P.	place|abstract[123]	giv|giv[123]	coref|coref	12-41|12-41[144_123]
11-2	2140-2150	falciparum	abstract[123]	giv[123]	_	_
11-3	2151-2153	is	_	_	_	_
11-4	2154-2157	one	abstract[124]	giv[124]	_	_
11-5	2158-2161	the	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
11-6	2162-2166	most	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
11-7	2167-2173	lethal	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
11-8	2174-2181	species	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
11-9	2182-2184	of	abstract[124]|abstract[125]	giv[124]|new[125]	_	_
11-10	2185-2188	the	abstract[124]|abstract[125]|animal[127]	giv[124]|new[125]|giv[127]	_	_
11-11	2189-2196	malaria	abstract[124]|abstract[125]|abstract|animal[127]	giv[124]|new[125]|giv|giv[127]	coref	13-19
11-12	2197-2206	parasites	abstract[124]|abstract[125]|animal[127]	giv[124]|new[125]|giv[127]	_	_
11-13	2207-2211	that	_	_	_	_
11-14	2212-2218	infect	_	_	_	_
11-15	2219-2225	humans	person	new	_	_
11-16	2226-2227	,	_	_	_	_
11-17	2228-2231	and	_	_	_	_
11-18	2232-2234	is	_	_	_	_
11-19	2235-2246	responsible	_	_	_	_
11-20	2247-2250	for	_	_	_	_
11-21	2251-2254	the	abstract[129]	new[129]	_	_
11-22	2255-2262	highest	abstract[129]	new[129]	_	_
11-23	2263-2269	number	abstract[129]	new[129]	_	_
11-24	2270-2272	of	abstract[129]	new[129]	_	_
11-25	2273-2280	serious	abstract[129]|abstract[130]	new[129]|new[130]	_	_
11-26	2281-2292	pathologies	abstract[129]|abstract[130]	new[129]|new[130]	_	_
11-27	2293-2303	associated	_	_	_	_
11-28	2304-2308	with	_	_	_	_
11-29	2309-2312	the	abstract[131]	giv[131]	_	_
11-30	2313-2320	disease	abstract[131]	giv[131]	_	_
11-31	2321-2322	.	_	_	_	_

#Text=In this work , we performed a comparative analysis of the serological reactivity of total antimalarial antibodies obtained by a commercial ELISA using recombinant antigens from Plasmodium sp . , compared to an in-house ELISA , using crude extract of P. falciparum 3D7 .
12-1	2323-2325	In	_	_	_	_
12-2	2326-2330	this	abstract[132]	new[132]	_	_
12-3	2331-2335	work	abstract[132]	new[132]	_	_
12-4	2336-2337	,	_	_	_	_
12-5	2338-2340	we	person	acc	ana	13-3
12-6	2341-2350	performed	_	_	_	_
12-7	2351-2352	a	abstract[134]	new[134]	_	_
12-8	2353-2364	comparative	abstract[134]	new[134]	_	_
12-9	2365-2373	analysis	abstract[134]	new[134]	_	_
12-10	2374-2376	of	abstract[134]	new[134]	_	_
12-11	2377-2380	the	abstract[134]|abstract[135]	new[134]|new[135]	_	_
12-12	2381-2392	serological	abstract[134]|abstract[135]	new[134]|new[135]	_	_
12-13	2393-2403	reactivity	abstract[134]|abstract[135]	new[134]|new[135]	_	_
12-14	2404-2406	of	abstract[134]|abstract[135]	new[134]|new[135]	_	_
12-15	2407-2412	total	abstract[134]|abstract[135]|substance[136]	new[134]|new[135]|giv[136]	_	_
12-16	2413-2425	antimalarial	abstract[134]|abstract[135]|substance[136]	new[134]|new[135]|giv[136]	_	_
12-17	2426-2436	antibodies	abstract[134]|abstract[135]|substance[136]	new[134]|new[135]|giv[136]	_	_
12-18	2437-2445	obtained	_	_	_	_
12-19	2446-2448	by	_	_	_	_
12-20	2449-2450	a	abstract[137]	giv[137]	coref	12-33[141_137]
12-21	2451-2461	commercial	abstract[137]	giv[137]	_	_
12-22	2462-2467	ELISA	abstract[137]	giv[137]	_	_
12-23	2468-2473	using	_	_	_	_
12-24	2474-2485	recombinant	substance[138]	giv[138]	coref	13-6[148_138]
12-25	2486-2494	antigens	substance[138]	giv[138]	_	_
12-26	2495-2499	from	substance[138]	giv[138]	_	_
12-27	2500-2510	Plasmodium	substance[138]|substance|abstract[140]	giv[138]|giv|giv[140]	_	_
12-28	2511-2513	sp	substance[138]|abstract[140]	giv[138]|giv[140]	_	_
12-29	2514-2515	.	_	_	_	_
12-30	2516-2517	,	_	_	_	_
12-31	2518-2526	compared	_	_	_	_
12-32	2527-2529	to	_	_	_	_
12-33	2530-2532	an	abstract[141]	giv[141]	coref	13-30[154_141]
12-34	2533-2541	in-house	abstract[141]	giv[141]	_	_
12-35	2542-2547	ELISA	abstract[141]	giv[141]	_	_
12-36	2548-2549	,	_	_	_	_
12-37	2550-2555	using	_	_	_	_
12-38	2556-2561	crude	object[142]	new[142]	_	_
12-39	2562-2569	extract	object[142]	new[142]	_	_
12-40	2570-2572	of	object[142]	new[142]	_	_
12-41	2573-2575	P.	object[142]|place|abstract[144]	new[142]|giv|giv[144]	coref|coref	13-6[146_0]|13-9[0_144]
12-42	2576-2586	falciparum	object[142]|abstract[144]	new[142]|giv[144]	_	_
12-43	2587-2590	3D7	object[142]|abstract[144]	new[142]|giv[144]	_	_
12-44	2591-2592	.	_	_	_	_

#Text=Thus , we showed that several other P. falciparum antigens are equally important for the serological diagnosis of malaria , as well as some recombinant antigens commonly used in commercial ELISA .
13-1	2593-2597	Thus	_	_	_	_
13-2	2598-2599	,	_	_	_	_
13-3	2600-2602	we	person	giv	_	_
13-4	2603-2609	showed	_	_	_	_
13-5	2610-2614	that	_	_	_	_
13-6	2615-2622	several	place[146]|substance[148]	giv[146]|giv[148]	coref	13-24[153_148]
13-7	2623-2628	other	place[146]|substance[148]	giv[146]|giv[148]	_	_
13-8	2629-2631	P.	place[146]|substance[148]	giv[146]|giv[148]	_	_
13-9	2632-2642	falciparum	abstract|substance[148]	giv|giv[148]	_	_
13-10	2643-2651	antigens	substance[148]	giv[148]	_	_
13-11	2652-2655	are	_	_	_	_
13-12	2656-2663	equally	_	_	_	_
13-13	2664-2673	important	_	_	_	_
13-14	2674-2677	for	_	_	_	_
13-15	2678-2681	the	abstract[149]|event[150]	new[149]|giv[150]	_	_
13-16	2682-2693	serological	abstract[149]|event[150]	new[149]|giv[150]	_	_
13-17	2694-2703	diagnosis	abstract[149]|event[150]	new[149]|giv[150]	_	_
13-18	2704-2706	of	abstract[149]|event[150]	new[149]|giv[150]	_	_
13-19	2707-2714	malaria	abstract[149]|event[150]|abstract	new[149]|giv[150]|giv	_	_
13-20	2715-2716	,	event[150]	giv[150]	_	_
13-21	2717-2719	as	event[150]	giv[150]	_	_
13-22	2720-2724	well	event[150]	giv[150]	_	_
13-23	2725-2727	as	event[150]	giv[150]	_	_
13-24	2728-2732	some	event[150]|substance[153]	giv[150]|giv[153]	_	_
13-25	2733-2744	recombinant	event[150]|person|substance[153]	giv[150]|new|giv[153]	_	_
13-26	2745-2753	antigens	event[150]|substance[153]	giv[150]|giv[153]	_	_
13-27	2754-2762	commonly	_	_	_	_
13-28	2763-2767	used	_	_	_	_
13-29	2768-2770	in	_	_	_	_
13-30	2771-2781	commercial	abstract[154]	giv[154]	_	_
13-31	2782-2787	ELISA	abstract[154]	giv[154]	_	_
13-32	2788-2789	.	_	_	_	_
